Tuesday, November 4, 2025

Latest

KetamineOne Adds Two Texas Locations To Clinical Network

KetamineOne Capital (NEO: MEDI) has continued to expand its presence across North America. The firm this morning announced that it has entered into a letter of intent for two additional ketamine clinics, which are to be located in Texas.

The additional footprint south of the border is to come via an arranged partnership with Illumma LLC, whom has a clinic in Austin as well as Bee Cave, Texas. The arrangement will bring the firms total stateside footprint to six clinics.

The two clinics from Illumma fit well with KetamineOne’s current model, in that they already offer ketamine infusion, which focuses on mental health, mood disorders, and chronic pain. The locations are to be jointed supported via KetamineOne’s existing clinical network.

“Illumma’s two existing clinics have already contributed to the improved mental health of their patients by applying innovative ketamine infusion therapies like those offered in Ketamine One’s clinical network. We expect that this arrangement will attract other partnerships or even acquisition targets, and yield further expansion opportunities across the United States,” commented Adam Deffett, the interim CEO of KetamineOne.

Under the terms of the arrangement, KetamineOne is to pay total consideration of $0.98 million for the partnership. Payment is to be split equally between common share and cash, with $350,000 of the cash consideration to be allocated for the development of additional clinics.

The addition of further clinics to KetamineOne’s network follows a major development announced last week, wherein the firm is to deploy Cognetivity Neuroscience’s (CSE: CGN) cognitive assessment tool across its North American network for use in monitoring both treatment-resistant depression as well as PTSD.

KetamineOne Capital last traded at $1.35 on the Neo Exchange.


FULL DISCLOSURE: KetamineOne is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover KetamineOne on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

PMET Resources: Lithium Feasibility Study Sees Economics Tumble

Gold Is Not Rising. Confidence Is Collapsing | Todd “Bubba” Horwitz

IAMGOLD: The Quebec Buying Spree

Recommended

Altamira Gold Adds Second Drill Rig To Ongoing Exploration Program Targeting Gold Porphyry’s

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Related News

Cognetivity’s Assessment Tool To Be Deployed At KetamineOne Clinics Across North America

Cognetivity Neurosciences (CSE: CGN) will soon see its cognitive assessment tool for the early detection...

Wednesday, September 1, 2021, 08:22:59 AM

KetamineOne Expands Offerings Of IRP Health With New Partnership

KetamineOne Capital (NEO: MEDI) is evidently looking to expanding its service offerings. The firm this...

Tuesday, September 14, 2021, 08:42:53 AM

KetamineOne Sees Subsidiary Assist In Ketamine Clinical Trials

Ketamine continues to be a hot topic in terms of clinical trials, with KGK Science,...

Wednesday, October 6, 2021, 09:16:49 AM

Ketamine One: Corporate Overview

KetamineOne Capital Ltd. (NEO: MEDI) is a Vancouver-based wellness company with a focus on becoming...

Wednesday, August 18, 2021, 02:33:00 PM

KetamineOne Brings Scent-Enabled Virtual Reality To Psychedelic Therapy

KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments....

Wednesday, August 4, 2021, 08:12:47 AM